Recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers NCT03564340 Conditions Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more Locations University of Alabama_6th Ave — Birmingham, Alabama, United States Massachusetts General Hospital — Boston, Massachusetts, United States Dana Farber / Harvard Cancer Center — Boston, Massachusetts, United States Mayo Clinic - Rochester — Rochester, Minnesota, United States View all 52 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT01853644 Conditions Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +25 more Locations Northwestern University — Chicago, Illinois, United States CDH-Delnor Health System - Northwestern Medicine Cancer Center — Warrenville, Illinois, United States View Trial Details
